Experience in preparing obese patients for infertility treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To study whether Reduxin Forte can be used in obese patients planning IVF. Subjects and methods. Thirty women with grade 1 obesity were examined and treated. Along with physical exercises and diet, Reduxin Forte (sibutramine 10-15 mg/day + metformin 850 mg/day) was used in the patients for 3 months. Anthropometric and carbohydrate metabolic parameters and the oxidative stress marker 8-0H-deoxyguanosine (8-0HdG) were estimated before and after treatment. Results. Prior to and following treatment, there were reductions in weight by 10.8% (90.597+5.79 vs. 80.773+5.58 kg; p = 0.017), BMI (33.324+1.53 vs. 29.719+1.55; p = 0.002), waist (96.733+3.92 vs. 89.133+3.91 cm; p = 0.008) and hip (114.067+4.40 vs. 107.733+3.54 cm; p = 0.028) circumferences. It should be emphasized that there were also decreases in insulin levels (15.271+2.67vs. 10.049+1.72pU/ml;p = 0.002), H0MA index (3.673+0.67 vs. 2.28+0.41; p < 0.001), and the levels of the oxidative stress marker 8-0HdG (0.361+0.082 vs. 0.240+0.029 ng/ml; p = 0.007). Conclusion. Three-month use of Reduxin Forte in patients with grade I obesity, who planned IVF, improved anthropometric parameters, normalized carbohydrate metabolism, and decreased 8-0HdG levels. Pregnancy after VF and in a natural cycle occurred in 8/18 (44.4%) and 8/26 (30.7%) of women, respectively.

Full Text

Restricted Access

About the authors

Tamara V. Zhuk

Altai State Medical University, Ministry of Health of the Russian Federation; Siberian Institute of Human Reproduction and Genetics

Svetlana D. Yavorskaya

Altai State Medical University, Ministry of Health of the Russian Federation

Vyacheslav V. Vostrikov

Siberian Institute of Human Reproduction and Genetics

Email: wkoctar@mail.ru

Vladimir M. Nagaitsev

Siberian Institute of Human Reproduction and Genetics

Email: ivfaltai@mail.ru

Alexey O. Kotov

Siberian Institute of Human Reproduction and Genetics

Email: 501077@bk.ru

References

  1. Correa A., Marcinkevage J. Prepregnancy obesity and the risk of birth defects: an update. Nutr Rev. 2013; 71(Suppl. 1): 68-77. doi: 10.1111/nure.12058.
  2. Dolin C.D., Kominiarek M.A. Pregnancy in women with obesity. Obstet Gynecol Clin North Am. 2018; 45: 217-32. http://dx.doi.org/10.1016/j.ogc.2018.01.005
  3. Sneed M.L., Uhler M.L., Grotjan H.E., et al. Body mass index: impact on IVF success appears age-related. Hum Reprod. 2008; 23(8): 1835-9. https://doi. org/10.1093/humrep/den188
  4. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol.2016; 4(12): 1025-1036. doi: 10.1016/S2213-8587(16)30217-0.
  5. Rasmussen S.A., Chu S.Y., Kim S.Y., Schmid C.H., Lau J. Maternal obesity and risk of neural tube defects: a metaanalysis. Am. J. Obstet. Gynecol. 2008; 198(6): 611-9. doi: 10.1016/j.ajog.2008.04.021.
  6. Poston L., Caleyachetty R., Cnattingius S., Corvalan C., Uauy R., Herring S., et al. Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol. 2018; 4: 1025-36. doi: 10.1016/ S2213-8587(16)30217-0.
  7. Most J., Marlatt K. L., Altazan A. D., Redman L. M. Advances in assessing body composition during pregnancy. Eur J. Clin Nutr. 2018; 72: 645-56. doi: 10.1038/s41430-018-0152-8.
  8. Bozkurt L., Gobl C. S., Hormayer A.T., Luger A., Pacini G., Kautzky-Willer A. The impact of preconceptional obesity on trajectories of maternal lipids during gestation. Sci. Rep.2016; 6: 29971. doi: 10.1038/srep29971.
  9. Burton G.J., Jauniaux E. Oxidative stress. Best Practice & Research Clinical Obstetrics & Gynaecology. 2011; 25(3): 287-99. doi: 10.1016/j. bpobgyn.2010.10.016
  10. Alcala M., Sanchez-Vera I., Sevillano J., Herrero L., Serra D., Ramos M.P., et al. Vitamin E. reduces adipose tissue fibrosis, inflammation, and oxidative stress and improves metabolic profile in obesity. Obesity. 2015; 23(8): 1598-1606. doi: 10.1002/oby.21135
  11. Agarwal A., Aziz N., Rizk B. Studies on Women’s Health. HumanaPress, NewYork; 2013; 33-60. doi:https://doi.org/10.1007/978-1-62703-041-0.
  12. Matsuda M., Shimomura I. Increased oxidative stress in obesity: implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes. Res. Clin. Pract. 2013; 7: 330-341. doi: 10.1016/j.orcp.2013.05.004
  13. Agarwal A., Aponte-Mellado A., Premkumar B.J., et al. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012; 10(1): 49. doi: 10.1186/1477-7827-10-49.
  14. Savini I., Catani M.V., Evangelista D., Gasperi V., Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. Int. J. Mol. Sci. 2013; 14: 10497-538. doi: 10.3390/ijms140510497.
  15. Alcala M., Calderon-Dominguez M., Serra D., Herrero L., Ramos M.P., Viana M. Short-term vitamin E. treatment impairs reactive oxygen species signaling required for adipose tissue expansion, resulting in fatty liver and insulin resistance in obese mice. PLoS One 2017; 23-56. https://doi.org/10.1371/ journal.pone.0186579
  16. Wu F., Tian F.J., Lin Y. Oxidative stress in placenta: health and diseases. Biomed. Res. Int. 2015; 293271. https://doi.org/10.1155/2015/293271
  17. Malti N., Merzouk H., Merzouk S.A., Loukidi B., Karaouzene N., Malti A., et al. Oxidative stress and maternal obesity: feto-placental unit interaction. Placenta 2014; 35: 411-6. doi: 10.1016/j.placenta.2014.03.010.
  18. ck C.Y., Kim E.H., Choi D.J., Lee H.J., Hahm K.B., Chung M.H. 8-Hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicatedgastrointestinal diseases. World J. Gastroenterol. 2012; 18(4): 302-8. doi: 10.3748/wjg.v18.i4.302.
  19. Nguyen D.M., El-Serag H.B. The epidemiology of obesity. Gastroenterol Clin North Am. 2010; 39(1):1-7. https://doi.org/10.1016/ j.gtc.2009.12.014
  20. Дедов И.И., Романцова Т.И., Шестакова М.В. Рациональный подход к терапии пациентов с СД2 и ожирением: итоги всероссийской наблюдательной программы «АВРОРА» Ожирение и метаболизм. 2018; 15(4): 48-58.
  21. Востриков В.В., Маркова Е.А., Кузнецова Т.А., Елизарьев А.Ю. Этиология и патогенез синдрома гиперстимуляции яичников. Современные аспекты диагностики, лечения и профилактики. Барнаул: Алтайский медицинский университет, 2016. 60 с.
  22. Иванова А.Р. Меди ко-психологические особенности женщин во время лечения бесплодия: автореф. дис. канд. мед. наук. М., 2010.
  23. Жук Т.В., Яворская С.Д., Востриков В.В., Немцева Г.В. Прогноз эффективности экстракорпорального оплодотворения у пациенток с трубно-перитонеальным бесплодием и ожирением. Российский вестник акушера-гинеколога. 2019; 19(1): 66-9. doi: 10.17116/rosakush20191901166

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies